Abstract
Soluble epoxide hydrolase (sEH) plays a major role in regulating vascular epoxyeicosatrienoic acid metabolism and function, and substituted urea derivatives that inhibit sEH activity reduce blood pressure in hypertensive rats. We found that substituted urea derivatives containing a dodecanoic acid group, besides effectively inhibiting sEH, increased peroxisome proliferator-activated receptor (PPAR) α activity. In PPARα transfected COS-7 cells, treatment with 10 μM N-cyclohexyl-N′-dodecanoic acid urea (CUDA) or N-adamantanyl-N′-dodecanoic acid urea (AUDA) produced 6- and 3-fold increases, respectively, in PPARα activation. Neither CUDA nor AUDA activated PPARδ or PPARγ directly, indicating selectivity for PPARα. CUDA did not alter PPARα protein expression, and it competitively inhibited the binding of Wy-14643 (pirinixic acid) to the ligand binding domain of PPARα, suggesting that it functions as a PPARα ligand. CUDA and AUDA were metabolized to chain-shortened β-oxidation products, a process that reduced their potency as sEH inhibitors and their ability to bind and activate PPARα. N,N′-Dicylclohexylurea and N-cyclohexyl-N′-dodecylurea, sEH inhibitors that do not contain a carboxylic acid group, did not activate PPARα. In HepG2 cells, CUDA increased the expression of the PPARα-responsive gene carnitine palmitoyltransferase 1A. We conclude that CUDA and AUDA, by virtue of their carboxylic acid substitution, activate PPARα in addition to potently inhibiting sEH. Further development of these compounds could lead to a class of agents with hypotensive and lipid-lowering properties that may be valuable for the prevention and treatment of cardiovascular disease.
Footnotes
-
The work at the University of Iowa was supported in part by American Heart Association Scientist Development Grant 0230096N (to X.F.), National Institutes of Health Grants HL072845 (to A.A.S.), HL070860 (to N.L.W.), and HL062984 (to N.L.W. and A.A.S.), and a Veterans Administration Merit Award (to N.L.W.). The work at the University of California (Davis) was supported by National Institutes of Health Grants HL59699 and ES02710, the Superfund Basic Research Program P42 ES04699, and National Institute of Environmental Health Sciences Centers P30 ES05707 and P01 ES11269 (to B.D.H.).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.105.085605.
-
ABBREVIATIONS: EET, epoxyeicosatrienoic acid; DHET, dihydroxyeicosatrienoic acid; sEH, soluble epoxide hydrolase; DCU, N,N′-dicylclohexylurea; CDU, N-cyclohexyl-N′-dodecylurea; CUDA, N-cyclohexyl-N′-dodecanoic acid urea; AUDA, N-adamantidyl-N′-dodecanoic acid urea; PPAR, peroxisome proliferator-activated receptor; DMEM, Dulbecco's modified Eagle's medium; β-Gal, β-galactosidase; DMSO, dimethyl sulfoxide; CPT1A, carnitine palmitoyltransferase 1A; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Wy-14643, pirinixic acid; HPLC, high-performance liquid chromatography; LC/MS-MS, liquid chromatography combined with tandem mass spectrometry; GW7647, 2-(4-(2-(1-cyclohexanebutyl-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid; TLC, thin-layer chromatography.
- Received March 2, 2005.
- Accepted March 25, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|